Generali Investments Towarzystwo Funduszy Inwestycyjnych Grows Position in Exact Sciences Co. (NASDAQ:EXAS)

Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 33.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,000 shares of the medical research company’s stock after acquiring an additional 6,000 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Exact Sciences were worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Thompson Investment Management Inc. boosted its position in shares of Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after acquiring an additional 36,505 shares during the last quarter. WCM Investment Management LLC boosted its position in shares of Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock valued at $12,388,000 after acquiring an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. boosted its position in shares of Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after acquiring an additional 11,800 shares during the last quarter. Zacks Investment Management acquired a new position in shares of Exact Sciences during the 3rd quarter valued at about $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after acquiring an additional 125,192 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Down 1.4 %

EXAS stock opened at $47.82 on Friday. The company’s 50 day moving average price is $54.17 and its 200 day moving average price is $59.79. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The firm has a market capitalization of $8.88 billion, a price-to-earnings ratio of -8.59 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. On average, equities research analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Canaccord Genuity Group decreased their target price on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Scotiabank upped their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research report on Monday. Jefferies Financial Group upped their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler decreased their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.94.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.